Egetis Therapeutics AB (publ) (STO: EGTX)
Sweden
· Delayed Price · Currency is SEK 5.80
-0.09 (-1.53%)
Aug 30, 2024, 5:29 PM CET
Egetis Therapeutics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Operating Revenue | 259.1 | 247.2 | 217.9 | 187.8 | 151.5 | 96.5 | Upgrade
|
| Other Revenue | 46.4 | 44.9 | 44.7 | 39.1 | 26.9 | 13.2 | Upgrade
|
| Revenue | 305.5 | 292.1 | 262.6 | 226.9 | 178.4 | 109.7 | Upgrade
|
| Revenue Growth (YoY) | 6.41% | 11.23% | 15.73% | 27.19% | 62.63% | 3224.24% | Upgrade
|
| Cost of Revenue | 72.1 | 72.5 | 68.7 | 61.5 | 57.7 | 46.8 | Upgrade
|
| Gross Profit | 233.4 | 219.6 | 193.9 | 165.4 | 120.7 | 62.9 | Upgrade
|
| Selling, General & Admin | 34.1 | 36.1 | 36.2 | 30.4 | 51.5 | 10.2 | Upgrade
|
| Other Operating Expenses | 18.9 | 14.9 | 14.2 | 4.6 | 2.6 | 0.6 | Upgrade
|
| Operating Expenses | 53 | 51 | 50.4 | 35 | 54.1 | 10.8 | Upgrade
|
| Operating Income | 180.4 | 168.6 | 143.5 | 130.4 | 66.6 | 52.1 | Upgrade
|
| Interest Expense | -134.1 | -129.3 | -62.5 | -44.1 | -43.9 | -21 | Upgrade
|
| Interest & Investment Income | 49.3 | 53.4 | 9.5 | - | 0.2 | 0.5 | Upgrade
|
| Currency Exchange Gain (Loss) | -2 | -2.2 | -16.4 | 0.1 | -4.9 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 19.7 | - | - | 0.2 | -1.9 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | 113.3 | 90.5 | 74.1 | 86.6 | 16.1 | 31.5 | Upgrade
|
| Gain (Loss) on Sale of Investments | -61.8 | -61.8 | 90.9 | 3 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -277.8 | -277.8 | 98 | 172.9 | 85.9 | 0.1 | Upgrade
|
| Asset Writedown | 142.7 | - | - | - | - | 98.1 | Upgrade
|
| Pretax Income | -83.6 | -249.1 | 263 | 262.5 | 102 | 129.7 | Upgrade
|
| Income Tax Expense | -14.2 | -48.5 | 55.7 | 52.8 | 30.2 | 27 | Upgrade
|
| Net Income | -69.4 | -200.6 | 207.3 | 209.7 | 71.8 | 102.7 | Upgrade
|
| Net Income to Common | -69.4 | -200.6 | 207.3 | 209.7 | 71.8 | 102.7 | Upgrade
|
| Net Income Growth | - | - | -1.14% | 192.06% | -30.09% | - | Upgrade
|
| Shares Outstanding (Basic) | 65 | 59 | 59 | 59 | 59 | - | Upgrade
|
| Shares Outstanding (Diluted) | 65 | 59 | 59 | 59 | 59 | - | Upgrade
|
| Shares Change (YoY) | 2.25% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | -1.06 | -3.40 | 3.51 | 3.55 | 1.22 | - | Upgrade
|
| EPS (Diluted) | -1.06 | -3.40 | 3.51 | 3.55 | 1.22 | - | Upgrade
|
| EPS Growth | - | - | -1.14% | 192.06% | - | - | Upgrade
|
| Free Cash Flow | 69.2 | 97.7 | 52.8 | 55.6 | 96.2 | 41.9 | Upgrade
|
| Free Cash Flow Per Share | 1.06 | 1.66 | 0.90 | 0.94 | 1.63 | - | Upgrade
|
| Gross Margin | 76.40% | 75.18% | 73.84% | 72.90% | 67.66% | 57.34% | Upgrade
|
| Operating Margin | 59.05% | 57.72% | 54.65% | 57.47% | 37.33% | 47.49% | Upgrade
|
| Profit Margin | -22.72% | -68.68% | 78.94% | 92.42% | 40.25% | 93.62% | Upgrade
|
| Free Cash Flow Margin | 22.65% | 33.45% | 20.11% | 24.50% | 53.92% | 38.20% | Upgrade
|
| EBITDA | 181.5 | 169.5 | 143.9 | 131.6 | 67.3 | 52.6 | Upgrade
|
| EBITDA Margin | 59.41% | 58.03% | 54.80% | 58.00% | 37.72% | 47.95% | Upgrade
|
| D&A For EBITDA | 1.1 | 0.9 | 0.4 | 1.2 | 0.7 | 0.5 | Upgrade
|
| EBIT | 180.4 | 168.6 | 143.5 | 130.4 | 66.6 | 52.1 | Upgrade
|
| EBIT Margin | 59.05% | 57.72% | 54.65% | 57.47% | 37.33% | 47.49% | Upgrade
|
| Effective Tax Rate | - | - | 21.18% | 20.11% | 29.61% | 20.82% | Upgrade
|
| Revenue as Reported | 305.5 | 292.1 | 262.6 | 226.9 | 178.4 | 109.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.